# **Supplementary Material**

East Asian-specific novel loci associated with late-onset Alzheimer's disease: the GARD cohort Genome-wide study

### SUPPLEMENTARY METHODS

#### GARD Cohort

GARD (Gwangju Alzheimer's & Related Dementias) cohort is a group that has been tracked since 2010 after recruiting local senior citizens aged 60 or older for research on Alzheimer's disease and dementia. Most of the subjects are recruited at the Early Dementia Examination Center in Gwangju Bitgoeul Senior Health Town to check basic personal information and academic background, history, family history, and drug use, and conduct biometric (EEG, PPG, impedance) tests and K-MMSE (Korean Mini-Mental State Examination) tests to determine whether dementia is judged or not. Among the subjects whose K-MMSE assessment has been completed, the MMSE score > 27 is selected, and the number of subjects recruited is currently 13,845. Additional full clinical examination is conducted for those who wish to conduct a thorough examination and those who agree to the study after conducting the basic examination. Clinical evaluation is conducted through brain imaging information of subjects using SNSB (Seoul Neuropsychological Screening Battery)[1] test and 3T MRI (Skyra, Siemens) single scanner. All diagnoses are evaluated by dementia specialists in neurology and psychiatry at Chosun University Hospital and Chonnam National University Hospital. The diagnosed subjects are also being tested for blood and CSF, blood test (blood count, cholesterol, blood sugar, thyroid function test), and gene test through purification. Cognitively normal (CN) subjects had no evidence of neurological disorder and impairment in cognitive function or activities of daily living.

Subjects who have less than three years of education, have a history of brain disease and mental health, or are taking related drugs, those who have a high level of drinking power and depression were excluded. The clinical diagnosis of probable AD was determined using NINCDS/ADRDA criteria.[2] To identify the Asian specific variants, we performed a replication study by using Japanese datasets.

# SNP genotyping

Genomic DNA from GARD cohort was extracted from peripheral blood leukocytes that were isolated from whole blood collected in EDTA tube. Of the total subjects, 5,570 blood samples were finally used for genomic analysis, except for diagnostic uncertainty, no blood, and insufficient DNA concentration among all subjects. The samples were genotyped using the KNIH Biobank Array[3] as part of the discovery sample. Affymetrix Power Tools (APT) were used to process all CEL files. Dish QC (DQC) values were generated and used to remove samples with DQC<0.82. For better quality control of markers, low quality markers that selected by Health Ministry were removed. To go through a better sample QC process, low quality markers were removed by SNPolisher. The 4,391 samples used KNIH Biobank array v1.0, while 1,179 samples used KNIH Biobank array v1.1 which is a more supplemented by Koreans. And we used both versions together for analysis to use a large number of samples and extracted only a common SNPs. The replication data was genotyped with Affymetrix GeneChip 6.0 microarrays, and includes 905,422 variants for 2,022 objects (1,007 AD cases and 1,015 controls)[4].

## Quality control

We performed QC under the same conditions for each chip version using the PLINK v1.90 package. SNPs with genotype call rate (GCR) < 95%, a minor allele frequency

(MAF) <0.01, or significant deviation from the Hardy-Weinberg equilibrium (HWE) ( $P<1\times10^{-6}$ ) were excluded. Samples with individual call rate < 95%, gender inconsistency between reported and analysis of X-chromosome SNPs, extremely low or high genome-wide heterozygosity ( $\pm3$  S.D from the mean). After performing QC for SNPs and samples, 4,011 samples and 518,326 SNPs were passed from KNIH chip v1.0 and 1,117 samples and 577,694 SNPs were passed from KNIH chip v1.1. For replication study, sample QC and marker QC were conducted on the same basis as discovery dataset, and finally 1,956 samples and 669,196 variants were used.

### **REFERENCES**

- [1] Y. Kang, D. Na, S.J.I.H.b.r. Hahn, and c. co, Seoul neuropsychological screening battery. (2003).
- [2] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS--ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 77 (2011) 333-333.
- [3] S. Moon, Y.J. Kim, S. Han, M.Y. Hwang, D.M. Shin, M.Y. Park, Y. Lu, K. Yoon, H.M. Jang, Y.K. Kim, T.J. Park, D.S. Song, J.K. Park, J.E. Lee, and B.J. Kim, The Korea Biobank Array: Design and Identification of Coding Variants Associated with Blood Biochemical Traits. Sci Rep 9 (2019) 1382.
- [4] A. Miyashita, A. Koike, G. Jun, L.S. Wang, S. Takahashi, E. Matsubara, T. Kawarabayashi, M. Shoji, N. Tomita, H. Arai, T. Asada, Y. Harigaya, M. Ikeda, M. Amari, H. Hanyu, S. Higuchi, T. Ikeuchi, M. Nishizawa, M. Suga, Y. Kawase, H. Akatsu, K. Kosaka, T. Yamamoto, M. Imagawa, T. Hamaguchi, M. Yamada, T. Morihara, M. Takeda, T. Takao, K. Nakata, Y. Fujisawa, K. Sasaki, K. Watanabe, K. Nakashima, K. Urakami, T. Ooya, M. Takahashi, T. Yuzuriha, K. Serikawa, S. Yoshimoto, R. Nakagawa, J.W. Kim, C.S. Ki, H.H. Won, D.L. Na, S.W. Seo, I. Mook-Jung, C. Alzheimer Disease Genetics, P. St George-Hyslop, R. Mayeux, J.L. Haines, M.A. Pericak-Vance, M. Yoshida, N. Nishida, K. Tokunaga, K. Yamamoto, S. Tsuji, I. Kanazawa, Y. Ihara, G.D. Schellenberg, L.A. Farrer, and R. Kuwano, SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One 8 (2013) e58618.